ArticleChina CDC weekly2026
Accessible Blood Based Biomarkers Reflecting Inflammation-Lipid Dysregulation in Silicosis Progression - Jiangsu Province, China, 2021-2024.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Silicosis, an occupational lung disease caused by exposure to silica dust, is characterized by persistent inflammation and lipid dysregulation. Clinicians typically rely on radiographic imaging and pulmonary function tests instead of accessible blood-based biomarkers to quantify inflammation-lipid imbalance and predict functional decline in disease management. What is added by this report?: We evaluate two novel hematological indices - Neutrophil-to-HDL Ratio (NHR) and Platelet-to-HDL Ratio (PHR) - in 160 patients with silicosis and 123 silica-exposed controls from Jiangsu Province, China. Both the NHR and PHR of patients in the silicosis group are significantly higher than those in the control group, with the highest levels observed in advanced stages (Stage II-III). Both ratios show significant negative correlations with lung function decline (FVC%, FEV What are the implications for public health practice?: NHR and PHR are low-cost, accessible biomarkers of inflammation-lipid dysregulation during the progression of silicosis. Incorporating these ratios into routine occupational health screening for silica-exposed workers could serve as a complementary method to radiographic examination or spirometry tests, thereby improving silicosis monitoring and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.